• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

工程化巨噬细胞:用于癌症治疗的纳米技术与基因操纵

Engineering Macrophages Nanotechnology and Genetic Manipulation for Cancer Therapy.

作者信息

Ding Xiaoling, Sun Xinchen, Cai Huihui, Wu Lei, Liu Ying, Zhao Yu, Zhou Dingjingyu, Yu Guiping, Zhou Xiaorong

机构信息

Department of Immunology, Nantong University, School of Medicine, Nantong, China.

Department of Gastroenterology, The Affiliated Hospital of Nantong University, Nantong, China.

出版信息

Front Oncol. 2022 Jan 6;11:786913. doi: 10.3389/fonc.2021.786913. eCollection 2021.

DOI:10.3389/fonc.2021.786913
PMID:35070992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8770285/
Abstract

Macrophages play critical roles in tumor progression. In the tumor microenvironment, macrophages display highly diverse phenotypes and may perform antitumorigenic or protumorigenic functions in a context-dependent manner. Recent studies have shown that macrophages can be engineered to transport drug nanoparticles (NPs) to tumor sites in a targeted manner, thereby exerting significant anticancer effects. In addition, macrophages engineered to express chimeric antigen receptors (CARs) were shown to actively migrate to tumor sites and eliminate tumor cells through phagocytosis. Importantly, after reaching tumor sites, these engineered macrophages can significantly change the otherwise immune-suppressive tumor microenvironment and thereby enhance T cell-mediated anticancer immune responses. In this review, we first introduce the multifaceted activities of macrophages and the principles of nanotechnology in cancer therapy and then elaborate on macrophage engineering nanotechnology or genetic approaches and discuss the effects, mechanisms, and limitations of such engineered macrophages, with a focus on using live macrophages as carriers to actively deliver NP drugs to tumor sites. Several new directions in macrophage engineering are reviewed, such as transporting NP drugs through macrophage cell membranes or extracellular vesicles, reprogramming tumor-associated macrophages (TAMs) by nanotechnology, and engineering macrophages with CARs. Finally, we discuss the possibility of combining engineered macrophages and other treatments to improve outcomes in cancer therapy.

摘要

巨噬细胞在肿瘤进展中发挥着关键作用。在肿瘤微环境中,巨噬细胞表现出高度多样的表型,并可能根据具体情况发挥抗肿瘤或促肿瘤功能。最近的研究表明,可以对巨噬细胞进行改造,使其以靶向方式将药物纳米颗粒(NPs)转运至肿瘤部位,从而发挥显著的抗癌作用。此外,经改造表达嵌合抗原受体(CARs)的巨噬细胞被证明能主动迁移至肿瘤部位,并通过吞噬作用清除肿瘤细胞。重要的是,到达肿瘤部位后,这些经过改造的巨噬细胞可显著改变原本具有免疫抑制作用的肿瘤微环境,从而增强T细胞介导的抗癌免疫反应。在这篇综述中,我们首先介绍巨噬细胞的多方面活动以及纳米技术在癌症治疗中的原理,然后详细阐述巨噬细胞工程——纳米技术或基因方法,并讨论此类经改造巨噬细胞的作用、机制和局限性,重点是利用活巨噬细胞作为载体将NP药物主动递送至肿瘤部位。本文综述了巨噬细胞工程的几个新方向,如通过巨噬细胞膜或细胞外囊泡转运NP药物、利用纳米技术对肿瘤相关巨噬细胞(TAMs)进行重编程以及用CARs改造巨噬细胞。最后,我们讨论了将经改造的巨噬细胞与其他治疗方法相结合以改善癌症治疗效果的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/024d/8770285/c38aefa5fa8f/fonc-11-786913-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/024d/8770285/d90989b0466f/fonc-11-786913-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/024d/8770285/f1f651cea480/fonc-11-786913-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/024d/8770285/a71e7de2e939/fonc-11-786913-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/024d/8770285/c38aefa5fa8f/fonc-11-786913-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/024d/8770285/d90989b0466f/fonc-11-786913-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/024d/8770285/f1f651cea480/fonc-11-786913-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/024d/8770285/a71e7de2e939/fonc-11-786913-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/024d/8770285/c38aefa5fa8f/fonc-11-786913-g004.jpg

相似文献

1
Engineering Macrophages Nanotechnology and Genetic Manipulation for Cancer Therapy.工程化巨噬细胞:用于癌症治疗的纳米技术与基因操纵
Front Oncol. 2022 Jan 6;11:786913. doi: 10.3389/fonc.2021.786913. eCollection 2021.
2
Harnessing anti-tumor and tumor-tropism functions of macrophages via nanotechnology for tumor immunotherapy.通过纳米技术利用巨噬细胞的抗肿瘤和肿瘤趋向性功能进行肿瘤免疫治疗。
Exploration (Beijing). 2022 Feb 25;2(3):20210166. doi: 10.1002/EXP.20210166. eCollection 2022 Jun.
3
CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies.嵌合抗原受体与超越:定制基于巨噬细胞的细胞疗法以攻克实体恶性肿瘤。
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002741.
4
Targeting Macrophages for Tumor Therapy.靶向肿瘤治疗中的巨噬细胞。
AAPS J. 2023 Aug 17;25(5):80. doi: 10.1208/s12248-023-00845-y.
5
Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.纳米治疗递送 c-myc 抑制剂靶向促肿瘤巨噬细胞并保留乳腺癌中的抗肿瘤巨噬细胞。
Theranostics. 2020 Jun 12;10(17):7510-7526. doi: 10.7150/thno.44523. eCollection 2020.
6
Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.CSF1R 靶向嵌合抗原受体修饰的 NK92MI&T 细胞对肿瘤相关巨噬细胞的影响。
Immunotherapy. 2018 Aug;10(11):935-949. doi: 10.2217/imt-2018-0012.
7
Turning adversity into opportunity: Small extracellular vesicles as nanocarriers for tumor-associated macrophages re-education.将逆境转化为机遇:小细胞外囊泡作为肿瘤相关巨噬细胞重编程的纳米载体
Bioeng Transl Med. 2022 Jun 9;8(1):e10349. doi: 10.1002/btm2.10349. eCollection 2023 Jan.
8
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery.用于癌症免疫治疗和药物递送的工程化巨噬细胞
Adv Mater. 2020 Oct;32(40):e2002054. doi: 10.1002/adma.202002054. Epub 2020 Aug 28.
9
Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy.工程化巨噬细胞的进展:癌症免疫治疗的新前沿。
Cell Death Dis. 2024 Apr 1;15(4):238. doi: 10.1038/s41419-024-06616-7.
10
Development of Toll-like Receptor Agonist-Loaded Nanoparticles as Precision Immunotherapy for Reprogramming Tumor-Associated Macrophages.Toll 样受体激动剂负载纳米颗粒的开发作为重新编程肿瘤相关巨噬细胞的精准免疫治疗。
ACS Appl Mater Interfaces. 2021 Jun 2;13(21):24442-24452. doi: 10.1021/acsami.1c01453. Epub 2021 May 19.

引用本文的文献

1
Beyond the Walls of Troy: A Scoping Review on Pharmacological Strategies to Enhance Drug Delivery Across the Blood-Brain Barrier and Blood-Tumor Barrier.超越特洛伊城墙:关于增强药物透过血脑屏障和血肿瘤屏障递送的药理学策略的范围综述
Int J Mol Sci. 2025 Jul 22;26(15):7050. doi: 10.3390/ijms26157050.
2
Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives.推进基于嵌合抗原受体(CAR)的实体瘤细胞疗法:挑战、治疗策略及展望
Mol Cancer. 2025 Jul 7;24(1):191. doi: 10.1186/s12943-025-02386-8.
3
Advancing Medical Applications of Cancer Nanotechnology: Highlighting Two Decades of the NCI'S Nanotechnology Characterization Laboratory Service to the Research Community.

本文引用的文献

1
Delivery of miR-26a Using an Exosomes-Based Nanosystem Inhibited Proliferation of Hepatocellular Carcinoma.使用基于外泌体的纳米系统递送miR-26a可抑制肝癌细胞增殖。
Front Mol Biosci. 2021 Sep 6;8:738219. doi: 10.3389/fmolb.2021.738219. eCollection 2021.
2
Cells-Based Drug Delivery for Cancer Applications.用于癌症治疗的基于细胞的药物递送
Nanoscale Res Lett. 2021 Sep 3;16(1):139. doi: 10.1186/s11671-021-03588-x.
3
Pro-tumoral functions of tumor-associated macrophage EV-miRNA.肿瘤相关巨噬细胞外泌体 miRNA 的促肿瘤功能。
推进癌症纳米技术的医学应用:凸显美国国立癌症研究所纳米技术表征实验室为研究界服务的二十年。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 May-Jun;17(3):e70020. doi: 10.1002/wnan.70020.
4
Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.用于癌症免疫治疗的细菌介导的肿瘤相关巨噬细胞原位工程
Cancers (Basel). 2025 Feb 20;17(5):723. doi: 10.3390/cancers17050723.
5
Macrophage Responses to Multicore Encapsulated Iron Oxide Nanoparticles for Cancer Therapy.巨噬细胞对用于癌症治疗的多核封装氧化铁纳米颗粒的反应。
ACS Omega. 2025 Jan 22;10(4):3535-3550. doi: 10.1021/acsomega.4c07883. eCollection 2025 Feb 4.
6
Therapeutic Properties of M2 Macrophages in Chronic Wounds: An Innovative Area of Biomaterial-Assisted M2 Macrophage Targeted Therapy.慢性伤口中M2巨噬细胞的治疗特性:生物材料辅助M2巨噬细胞靶向治疗的创新领域。
Stem Cell Rev Rep. 2025 Feb;21(2):390-422. doi: 10.1007/s12015-024-10806-3. Epub 2024 Nov 18.
7
The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer.免疫细胞疗法治疗癌症的进展与前景
Cell Transplant. 2024 Jan-Dec;33:9636897241231892. doi: 10.1177/09636897241231892.
8
Rational nanoparticle design: Optimization using insights from experiments and mathematical models.理性纳米粒子设计:从实验和数学模型中获得的见解进行优化。
J Control Release. 2023 Aug;360:772-783. doi: 10.1016/j.jconrel.2023.07.018. Epub 2023 Jul 22.
9
Surface-Engineered Monocyte Immunotherapy Combined Graphene Quantum Dots Effective Against Solid Tumor Targets.表面工程单核细胞免疫疗法联合石墨烯量子点有效针对实体瘤靶标。
Int J Nanomedicine. 2023 Apr 24;18:2127-2140. doi: 10.2147/IJN.S404486. eCollection 2023.
10
Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs.肿瘤相关巨噬细胞:人类和犬科动物癌症的预后和治疗靶点。
Front Immunol. 2023 Apr 5;14:1176807. doi: 10.3389/fimmu.2023.1176807. eCollection 2023.
Semin Cancer Biol. 2022 Nov;86(Pt 1):58-63. doi: 10.1016/j.semcancer.2021.08.001. Epub 2021 Aug 8.
4
The Biogenesis, Biological Functions, and Applications of Macrophage-Derived Exosomes.巨噬细胞衍生外泌体的生物发生、生物学功能及应用
Front Mol Biosci. 2021 Jul 21;8:715461. doi: 10.3389/fmolb.2021.715461. eCollection 2021.
5
CAR Macrophages for SARS-CoV-2 Immunotherapy.用于 SARS-CoV-2 免疫疗法的 CAR 巨噬细胞。
Front Immunol. 2021 Jul 23;12:669103. doi: 10.3389/fimmu.2021.669103. eCollection 2021.
6
Role of Virus-Induced Host Cell Epigenetic Changes in Cancer.病毒诱导的宿主细胞表观遗传改变在癌症中的作用。
Int J Mol Sci. 2021 Aug 3;22(15):8346. doi: 10.3390/ijms22158346.
7
Transcriptional repression shapes the identity and function of tissue macrophages.转录抑制决定组织巨噬细胞的身份和功能。
FEBS Open Bio. 2021 Dec;11(12):3218-3229. doi: 10.1002/2211-5463.13269. Epub 2021 Aug 14.
8
The Nanosystems Involved in Treating Lung Cancer.用于治疗肺癌的纳米系统。
Life (Basel). 2021 Jul 13;11(7):682. doi: 10.3390/life11070682.
9
Macrophage regulation of angiogenesis in health and disease.巨噬细胞在血管生成中的调控作用:健康与疾病。
Semin Cell Dev Biol. 2021 Nov;119:101-110. doi: 10.1016/j.semcdb.2021.06.010. Epub 2021 Jul 28.
10
DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges.用于癌症诊断与治疗的基于DNA和刺激响应型智能纳米载体:应用与挑战
Cancers (Basel). 2021 Jul 6;13(14):3396. doi: 10.3390/cancers13143396.